<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733653</url>
  </required_header>
  <id_info>
    <org_study_id>S6051</org_study_id>
    <nct_id>NCT02733653</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)</brief_title>
  <official_title>A Prospective, Multicenter, Single-arm Clinical Trial of Jetstream Atherectomy System for the Treatment of Japanese Patients With Symptomatic Occlusive Atherosclerotic Lesions in the Superficial Femoral and/ or Proximal Popliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the Jetstream
      Atherectomy System for the treatment of Japanese patients with symptomatic occlusive
      atherosclerotic lesions in native superficial femoral artery (SFA) and/or proximal popliteal
      arteries (PPA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, multicenter, single-arm trial evaluating the safety and efficacy of the
      Jetstream Atherectomy System in the treatment of symptomatic occlusive atherosclerotic
      lesions ≤150 mm in length located in the femoropopliteal arteries in subjects with symptoms
      classified as Rutherford categories 2-4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 25, 2016</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">June 29, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Procedural success rate</measure>
    <time_frame>during procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of distal emboli requiring additional treatment</measure>
    <time_frame>during procedure or within 24 hours post-index procedure</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in lesion stenosis</measure>
    <time_frame>during procedure</time_frame>
    <description>The difference between the percent stenosis prior to treatment with Jetstream and the percent stenosis following treatment with Jetstream.</description>
  </other_outcome>
  <other_outcome>
    <measure>Major Adverse Event (MAE) rate</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Primary patency</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
    <description>Percentage (%) of lesions that reach endpoint without a hemodynamically significant stenosis on Duplex Ultrasound (DUS) and without Target Lesion Revascularization (TLR) or, bypass of the target lesion.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assisted primary patency</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
    <description>Percentage (%) of lesions without TLR and those with TLR (not due to complete occlusion or by-pass) that reach endpoint without restenosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven TLR rate</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven Target Vessel Revascularization (TVR) rate</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Event rates</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of Rutherford Class</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Distribution of Rutherford Class as compared to baseline at 6 months and 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of primary and secondary sustained clinical improvement</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of hemodynamic improvement</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Jetstream Atherectomy System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Jetstream Atherectomy System</intervention_name>
    <description>A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA</description>
    <arm_group_label>Jetstream Atherectomy System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2-4

          -  Stenotic, restenotic or occlusive lesion(s) located in the native SFA and/or PPA of
             which meet all of the following criteria:

               -  Calcified lesions with degree of stenosis ≥70% or occlusions

               -  Guidewire must cross lesion(s) within the true lumen, without a sub-intimal
                  course

               -  Vessel diameter ≥3.0 mm and ≤6.0 mm

               -  Total lesion length (or series of lesions) ≤150mm

               -  Target lesion located at least 3 cm above the inferior edge of the femur by
                  visual estimate

          -  Patent infrapopliteal and popliteal artery

        Exclusion Criteria:

          -  Target lesion/vessel with in-stent restenosis

          -  Target lesion/vessel previously treated with drug-coated balloon &lt;12 months prior to
             the procedure

          -  Target lesion/vessel previously treated with any stent placement, atherectomy, laser
             or other debulking devices prior to the procedure

          -  Subjects who have undergone surgery or endovascular of the SFA/PPA in the target
             vessel to treat atherosclerotic disease within 3 months prior to the index procedure

          -  Use of drug-coated devices, atherectomy, laser or other debulking devices other than
             the Jetstream System, chronic total occlusion (CTO) devices or cutting balloon,
             Angioscore or similar devices in the target limb SFA/PPA during the index procedure

          -  History of major amputation in the target limb

          -  Subject has a history of coagulopathy or hypercoagulable bleeding disorder

          -  Subject with untreatable hemorrhagic disease or platelet count &lt;80,000mm3 or
             &gt;600,000mm3 as baseline assessment.

          -  Concomitant renal failure with a serum creatinine &gt;2.0 mg/dL

          -  Receiving dialysis or immunosuppressant therapy

          -  History of myocardial infarction, or stroke/cerebrovascular accident (CVA) within 6
             months prior to study enrollment

          -  Unstable angina pectoris at the time of the enrollment

          -  Septicemia at the time of enrollment

          -  Presence of other hemodynamically significant outflow lesions in the target limb
             requiring a planned surgical intervention or endovascular procedure within 30 days
             after the index procedure

          -  Presence of aneurysm in the target vessel

          -  Acute ischemia and/or acute thrombosis of the SFA/PPA prior to the index procedure

          -  Perforated vessel as evidenced by extravasation of contrast media prior to the index
             procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazushi Urasawa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tokeidai Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya Kyoritsu Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>454-0933</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokura Memorial Hospital</name>
      <address>
        <city>Kokura</city>
        <state>Fukuoka</state>
        <zip>802-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwaki Kyouritsu Hospital</name>
      <address>
        <city>Iwaki</city>
        <state>Fukushima</state>
        <zip>973-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokeidai Memorial Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Rosai Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <zip>660-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohama-City Eastern Hospital</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>230-8765</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kishiwada Tokushukai Hospital</name>
      <address>
        <city>Kishiwada</city>
        <state>Osaka</state>
        <zip>596-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasukabe Chuo General Hospital</name>
      <address>
        <city>Kasukabe</city>
        <state>Saitama</state>
        <zip>344-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nagano Red Cross Hospital</name>
      <address>
        <city>Nagano</city>
        <zip>380-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial Femoral Artery</keyword>
  <keyword>Proximal Popliteal Artery</keyword>
  <keyword>Endovascular therapy</keyword>
  <keyword>Atherectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

